|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 581 active entries
Parque Tecnologico de Zamudio, Edif. 801
Phone: +34 944 064 525
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
PROGENIKA BIOPHARMA, SA (www.progenika.com) was established in April 2000 as a leading company in Functional Genomics. The main aim of the Progenika Discovery Platform is the identification and validation of genes and proteins involved in human diseases, and their use in the development of new Drugs, Diagnostics and Pharmacogenomic Methods.
Progenika´s facilities are based in the Zamudio Technology Park, on the outskirts of Bilbao, Spain. Progenika’s laboratories are housed in the recently established BIOGUNE collaborative research centre. BIOGUNE is a centre devoted to Genomics, Proteomics and Metabolomics, where industrial and government-funded laboratories are working together. BIOGUNE is one of the 46 world-wide nodes of the HUMAN PROTEOME ORGANIZATION (HUPO).
Progenika is actively engaged in a wide range of R&D projects in collaboration with scientists and clinicians from universities, research institutes and hospitals. All current projects focus on human disease, a reflection of the true interests of the company. We apply our combined discovery platform to drug discovery programmes in cancer and neurological diseases. Therapeutic targets are identified through careful analysis of clinically typed human samples by using DNA chips and proteomics tools. Targets are then validated at the molecular level by Q-PCR and western-blot, and at the functional level by in vitro experiments with antibodies, siRNAs or antisense constructs.
Last update of this entry: March 19, 2004